Terms: = Endocrine gland cancer AND JUN, P05412, 3725, ENSG00000177606, AP1, c-Jun AND Prognosis
65 results:
1. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
[TBL] [Abstract] [Full Text] [Related]
2. SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation.
Gong TT; Liu FH; Xiao Q; Li YZ; Wei YF; Xu HL; Cao F; Sun ML; Jiang FL; Tao T; Ma QP; Qin X; Song Y; Gao S; Wu L; Zhao YH; Huang DH; Wu QJ
Commun Biol; 2024 Jan; 7(1):67. PubMed ID: 38195842
[TBL] [Abstract] [Full Text] [Related]
3. Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic cancer - An Overview.
Tarasiuk A; Mirocha G; Fichna J
Curr Treat Options Oncol; 2023 Dec; 24(12):1852-1869. PubMed ID: 38079061
[TBL] [Abstract] [Full Text] [Related]
4. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary Thyroid cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract] [Full Text] [Related]
5. Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk.
Qin H; Chen J; Bouchekioua-Bouzaghou K; Meng YM; Griera JB; Jiang X; Kong X; Wang M; Xu Q; Wong PP
J Transl Med; 2023 Oct; 21(1):702. PubMed ID: 37814317
[TBL] [Abstract] [Full Text] [Related]
6. TMPOP2 Inhibition Suppresses Pancreatic cancer Cell Migration and Development by Repressing The JNK/STAT3 Pathway.
Liang J; Cao H; Wang G; Wei L; Dong L; Chen G; Li Q; Zhu D
Adv Biol (Weinh); 2023 Dec; 7(12):e2300113. PubMed ID: 37469237
[TBL] [Abstract] [Full Text] [Related]
7. EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-jun signaling to promote the invasion of ovarian cancer cells.
Shen X; Jin X; Fang S; Chen J
Cell Mol Biol Lett; 2023 Jul; 28(1):53. PubMed ID: 37420173
[TBL] [Abstract] [Full Text] [Related]
8. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/Yap1/c-jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract] [Full Text] [Related]
9. Gene Differential Expression and Interaction Networks Illustrate the Biomarkers and Molecular Biological Mechanisms of Unsaponifiable Matter in Kanglaite Injection for Pancreatic Ductal Adenocarcinoma.
Xu B; Dan W; Zhang X; Wang H; Cao L; Li S; Li J
Biomed Res Int; 2022; 2022():6229462. PubMed ID: 35707377
[TBL] [Abstract] [Full Text] [Related]
10. ITGBL1 transcriptionally inhibited by JDP2 promotes the development of pancreatic cancer through the TGF-beta/Smad pathway.
Du T; Zhang K; Zhang Z; Guo A; Yu G; Xu Y
Braz J Med Biol Res; 2022; 55():e11989. PubMed ID: 35584452
[TBL] [Abstract] [Full Text] [Related]
11. TNF-α-producing macrophages determine subtype identity and prognosis via ap1 enhancer reprogramming in pancreatic cancer.
Tu M; Klein L; Espinet E; Georgomanolis T; Wegwitz F; Li X; Urbach L; Danieli-Mackay A; Küffer S; Bojarczuk K; Mizi A; Günesdogan U; Chapuy B; Gu Z; Neesse A; Kishore U; Ströbel P; Hessmann E; Hahn SA; Trumpp A; Papantonis A; Ellenrieder V; Singh SK
Nat Cancer; 2021 Nov; 2(11):1185-1203. PubMed ID: 35122059
[TBL] [Abstract] [Full Text] [Related]
12. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.
Machino H; Kaneko S; Komatsu M; Ikawa N; Asada K; Nakato R; Shozu K; Dozen A; Sone K; Yoshida H; Kato T; Oda K; Osuga Y; Fujii T; von Keudell G; Saloura V; Hamamoto R
Commun Biol; 2022 Jan; 5(1):39. PubMed ID: 35017636
[TBL] [Abstract] [Full Text] [Related]
13. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks.
Gulfidan G; Soylu M; Demirel D; Erdonmez HBC; Beklen H; Ozbek Sarica P; Arga KY; Turanli B
Arch Biochem Biophys; 2022 Jan; 715():109085. PubMed ID: 34800440
[TBL] [Abstract] [Full Text] [Related]
14. Meta-analysis identifying epithelial-derived transcriptomes predicts poor clinical outcome and immune infiltrations in ovarian cancer.
Li DF; Tulahong A; Uddin MN; Zhao H; Zhang H
Math Biosci Eng; 2021 Jul; 18(5):6527-6551. PubMed ID: 34517544
[TBL] [Abstract] [Full Text] [Related]
15. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-jun/VEGFR2 signaling axis in ovarian cancer.
Yang Y; Xia L; Wu Y; Zhou H; Chen X; Li H; Xu M; Qi Z; Wang Z; Sun H; Cheng X
Cancer Commun (Lond); 2021 Jun; 41(6):511-527. PubMed ID: 33939321
[TBL] [Abstract] [Full Text] [Related]
16. Ultrasound features of medullary thyroid cancer as predictors of biological behavior.
Zhao J; Zheng X; Gao M; Zhang S; Yun X; Chi J; Xu G
Cancer Imaging; 2021 Apr; 21(1):33. PubMed ID: 33836831
[TBL] [Abstract] [Full Text] [Related]
17. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
Liu XD; Zhang ZW; Wu HW; Liang ZY
Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
[TBL] [Abstract] [Full Text] [Related]
18. Effect of miR-184 on Proliferation and Apoptosis of Pancreatic Ductal Adenocarcinoma and Its Mechanism.
Li S; Li H; Ge W; Song K; Yuan C; Yin R
Technol Cancer Res Treat; 2020; 19():1533033820943237. PubMed ID: 32914707
[TBL] [Abstract] [Full Text] [Related]
19. TFAP2B, AP-1 and JAZF1 Expression in Tissues of Papillary Thyroid Carcinoma Patients; Clinical, Pathological and Prognostic Values.
A Abuderman A; A Harb O; M Gertallah L; Makki Almansour N
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2415-2421. PubMed ID: 32856873
[TBL] [Abstract] [Full Text] [Related]
20. miR-6089/MYH9/β-catenin/c-jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression.
Liu L; Ning Y; Yi J; Yuan J; Fang W; Lin Z; Zeng Z
Biomed Pharmacother; 2020 May; 125():109865. PubMed ID: 32058212
[TBL] [Abstract] [Full Text] [Related]
[Next]
